Search company, investor...

Aptamer Science



Date of IPO


About Aptamer Science

Aptamer Science is a bio venture company that develops therapeutics and diagnostic technologies. The company specializes in building the tamer technology platform. It is based in Seongnam, South Korea.

Headquarters Location

172, Dolmar-ro, Bundang-gu


South Korea

Missing: Aptamer Science's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Aptamer Science's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Aptamer Science Patents

Aptamer Science has filed 3 patents.

The 3 most popular patent topics include:

  • Nucleic acids
  • Transcription factors
  • Biotechnology
patents chart

Application Date

Grant Date


Related Topics




Application Date


Grant Date


Related Topics



Aptamer Science Frequently Asked Questions (FAQ)

  • Where is Aptamer Science's headquarters?

    Aptamer Science's headquarters is located at 172, Dolmar-ro, Bundang-gu, Seongnam.

  • What is Aptamer Science's latest funding round?

    Aptamer Science's latest funding round is IPO.

  • Who are the investors of Aptamer Science?

    Investors of Aptamer Science include AJU IB Investment.

  • Who are Aptamer Science's competitors?

    Competitors of Aptamer Science include TAGCyx Biotechnologies.

Compare Aptamer Science to Competitors


RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is one type of nucleic acid medicine.

Aptamer Group Logo
Aptamer Group

The Aptamer Group of companies focuses on the development of aptamer technologies. The firm develops nucleic acid aptamers for use in research & development, biomarker discovery, diagnostics or therapeutic developments. Aptamers are short ssDNA or ssRNA sequences that offer high-affinity and specificity to virtually all types of targets. Aptamers are versatile, cost-effective and offer a complementary or alternative solution to antibodies. We have over 60 years combined expertise in the development of nucleic acid aptamers to peptides, proteins, cells, tissue samples, micro-organisms and small molecules.

Aptamer Group

Aptamer Group specializes in developing optimer binders as synthetic alternatives to antibodies. It serves researchers and developers across the life sciences. The company was founded in 2008 and is based in York, U.K.

TAGCyx Biotechnologies

TAGCyx Biotechnologies is a research-based company that develops Xenoligo, a technology platform that enables high functional oligonucleotide drug discovery. The Xenoligo platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.

NOXXON Pharma Logo

NOXXON Pharma is a clinical-stage biopharmaceutical company whose core focus is on improving cancer treatment by targeting the tumor microenvironment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy.)


AptaBio is a South Korean pharmaceutical company focused on the discovery and development of selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.